Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffery R. Weiss, Theodore Logan, John M. Kirkwood, Michael S. Gordon, Jeffrey A. Sosman, Marc S. Ernstoff, Christopher P G Tretter, Walter J. Urba, John W. Smith, Kim A. Margolin, James W. Mier, Jared A. Gollob, Janice P. Dutcher, Michael B. Atkins

Research output: Contribution to journalArticle

599 Citations (Scopus)

Abstract

Purpose: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma. Patients and Methods: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m2 subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks. Results: One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 14 and 7 months (P = .14), and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2. Conclusion: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Renal Cell Carcinoma
Interferons
Interleukin-2
interferon alfa-2b
Neoplasm Metastasis
Bone and Bones
Survival
Liver
Interleukin-5
Neoplasms
Outpatients
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. / McDermott, David F.; Regan, Meredith M.; Clark, Joseph I.; Flaherty, Lawrence E.; Weiss, Geoffery R.; Logan, Theodore; Kirkwood, John M.; Gordon, Michael S.; Sosman, Jeffrey A.; Ernstoff, Marc S.; Tretter, Christopher P G; Urba, Walter J.; Smith, John W.; Margolin, Kim A.; Mier, James W.; Gollob, Jared A.; Dutcher, Janice P.; Atkins, Michael B.

In: Journal of Clinical Oncology, Vol. 23, No. 1, 01.01.2005, p. 133-141.

Research output: Contribution to journalArticle

McDermott, DF, Regan, MM, Clark, JI, Flaherty, LE, Weiss, GR, Logan, T, Kirkwood, JM, Gordon, MS, Sosman, JA, Ernstoff, MS, Tretter, CPG, Urba, WJ, Smith, JW, Margolin, KA, Mier, JW, Gollob, JA, Dutcher, JP & Atkins, MB 2005, 'Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma', Journal of Clinical Oncology, vol. 23, no. 1, pp. 133-141. https://doi.org/10.1200/JCO.2005.03.206
McDermott, David F. ; Regan, Meredith M. ; Clark, Joseph I. ; Flaherty, Lawrence E. ; Weiss, Geoffery R. ; Logan, Theodore ; Kirkwood, John M. ; Gordon, Michael S. ; Sosman, Jeffrey A. ; Ernstoff, Marc S. ; Tretter, Christopher P G ; Urba, Walter J. ; Smith, John W. ; Margolin, Kim A. ; Mier, James W. ; Gollob, Jared A. ; Dutcher, Janice P. ; Atkins, Michael B. / Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 1. pp. 133-141.
@article{e693ec644eb64654bbc8e9b28fbc741a,
title = "Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma",
abstract = "Purpose: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma. Patients and Methods: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m2 subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks. Results: One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2{\%} (22 of 95 patients) for HD IL-2 versus 9.9{\%} (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 14 and 7 months (P = .14), and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2. Conclusion: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.",
author = "McDermott, {David F.} and Regan, {Meredith M.} and Clark, {Joseph I.} and Flaherty, {Lawrence E.} and Weiss, {Geoffery R.} and Theodore Logan and Kirkwood, {John M.} and Gordon, {Michael S.} and Sosman, {Jeffrey A.} and Ernstoff, {Marc S.} and Tretter, {Christopher P G} and Urba, {Walter J.} and Smith, {John W.} and Margolin, {Kim A.} and Mier, {James W.} and Gollob, {Jared A.} and Dutcher, {Janice P.} and Atkins, {Michael B.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1200/JCO.2005.03.206",
language = "English (US)",
volume = "23",
pages = "133--141",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

AU - McDermott, David F.

AU - Regan, Meredith M.

AU - Clark, Joseph I.

AU - Flaherty, Lawrence E.

AU - Weiss, Geoffery R.

AU - Logan, Theodore

AU - Kirkwood, John M.

AU - Gordon, Michael S.

AU - Sosman, Jeffrey A.

AU - Ernstoff, Marc S.

AU - Tretter, Christopher P G

AU - Urba, Walter J.

AU - Smith, John W.

AU - Margolin, Kim A.

AU - Mier, James W.

AU - Gollob, Jared A.

AU - Dutcher, Janice P.

AU - Atkins, Michael B.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma. Patients and Methods: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m2 subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks. Results: One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 14 and 7 months (P = .14), and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2. Conclusion: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.

AB - Purpose: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma. Patients and Methods: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m2 subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks. Results: One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 14 and 7 months (P = .14), and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2. Conclusion: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=16644401873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644401873&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.206

DO - 10.1200/JCO.2005.03.206

M3 - Article

VL - 23

SP - 133

EP - 141

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -